Why Is Twist Bioscience Stock Soaring Monday?

Core Insights - Twist Bioscience Corporation reported a first-quarter 2026 loss of 50 cents per share, aligning with Wall Street expectations, while sales reached $103.70 million, a 17% year-over-year increase, surpassing both consensus and management guidance [1][4] Financial Performance - The adjusted EBITDA loss for the quarter was $13.4 million, an improvement from a loss of $16.3 million in the previous year [1][2] - Gross margin for the first quarter of fiscal 2026 increased to 52%, up from 48.3% a year ago [2] - The company had approximately $198 million in cash, cash equivalents, and short-term investments as of December 31, 2025 [3] Customer and Product Metrics - Twist shipped products to approximately 2,538 customers in Q1 2026, an increase from about 2,376 customers a year ago [2] - The company shipped approximately 271,000 genes in the quarter, compared to around 205,000 genes in the same period last year [2] Future Outlook - Twist Bioscience raised its fiscal 2026 sales guidance to $435 million-$440 million, compared to the previous range of $425 million-$435 million, with expectations for revenue growth balanced across DSPS and NGS [4] - The company anticipates gross margin to remain above 52% for fiscal 2026 and aims for adjusted EBITDA breakeven in Q4 of fiscal 2026 [4] Analyst Commentary - Analysts express confidence in the long-term revenue growth trajectory of the company, highlighting its aggressive investments in multiple markets that could lead to over 20% growth [6] - The company's strategy to moderate investments while scaling into the FOTF is viewed positively, as it may broaden the appeal of the company's story if executed effectively [6][7]